[A22-59] Cabozantinib (thyroid carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 15.12.2022
Project no.:
A22-59
Commission:
Commission awarded on 27.05.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine who have progressed during or after prior systemic therapy
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.
G-BA documents on this decision